UBS Group Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX) had its price objective upped by UBS Group from $115.00 to $117.00 in a note issued to investors on Thursday,MarketScreener reports. The firm currently has a “neutral” rating on the stock. UBS Group’s price target points to a potential upside of 13.12% from the company’s previous close.

Other analysts have also issued reports about the company. HC Wainwright restated a “buy” rating and issued a $136.00 target price on shares of BioNTech in a research note on Monday, September 8th. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a report on Monday. Wells Fargo & Company set a $150.00 price objective on shares of BioNTech and gave the company an “overweight” rating in a report on Tuesday, August 5th. Bank of America cut their target price on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a research report on Wednesday, October 22nd. Finally, Cowen reiterated a “hold” rating on shares of BioNTech in a research note on Monday. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.82.

BioNTech Price Performance

BNTX opened at $103.43 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The firm has a market cap of $23.29 billion, a P/E ratio of -64.64 and a beta of 1.45. BioNTech has a fifty-two week low of $81.20 and a fifty-two week high of $129.27. The firm has a 50-day moving average of $102.51 and a 200 day moving average of $105.04.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). The company had revenue of $1.78 billion for the quarter, compared to analysts’ expectations of $1.21 billion. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.81 EPS. BioNTech has set its FY 2025 guidance at EPS. On average, research analysts expect that BioNTech will post -3.88 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Rhenman & Partners Asset Management AB boosted its stake in BioNTech by 0.3% during the second quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company’s stock valued at $3,819,000 after buying an additional 120 shares during the period. Kennedy Capital Management LLC raised its holdings in shares of BioNTech by 0.8% in the 2nd quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock valued at $1,748,000 after acquiring an additional 127 shares in the last quarter. Probity Advisors Inc. boosted its position in shares of BioNTech by 5.7% during the 3rd quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock valued at $247,000 after acquiring an additional 135 shares during the last quarter. Profund Advisors LLC grew its holdings in shares of BioNTech by 3.6% during the second quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock worth $459,000 after purchasing an additional 149 shares in the last quarter. Finally, Banco Bilbao Vizcaya Argentaria S.A. grew its holdings in shares of BioNTech by 2.5% during the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 7,653 shares of the company’s stock worth $822,000 after purchasing an additional 186 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.